Home・Stock List・Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals Inc

Closed

1 2.04

Buy Sell

Overview

Share price change

24h

Current

Min

0.98

Max

Key metrics
By Trading Economics
Income	33M 28M
Sales	35M 35M
P/E Sector Avg	3.182 57.366
EPS	0.89
Profit margin	79.717
Employees	27
EBITDA	33M 28M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+246.53% upside

Dividends
By Acuity
Next Earnings	12 Nov 2026

Market Stats
By TradingEconomics
Market Cap	7.5M 33M
Previous open	-1.04
Previous close	1

Actinium Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

30 Aug 2026, 23:53 UTC

EUR/AUD is trading slightly higher in after-market hours, continuing its performance since Friday's close, though it remains near the lower end of its one-month range.

30 Aug 2026, 23:53 UTC

Correlated Moves

Gold/AUD is lower amid cautious sentiment following Barclays' warning of a potential commodity shock due to adverse weather and underinvestment in production.

30 Aug 2026, 23:53 UTC

Correlated Moves

Silver Ounce vs Euro is trading lower amid a broader decline in gold prices. Market sentiment is impacted by a Barclays report on potential commodity shocks.

30 Aug 2026, 23:51 UTC

Correlated Moves

The S&P 500 Index is lower amid broader market trends and cautious investor sentiment following Barclays' forecasts of a potential commodity shock.

30 Aug 2026, 23:51 UTC

Ethereum Drops 2.5% Amid Tech Stock Sell-Off and Economic Indicators, While Commodity Shock Looms from El Niño and Geopolitical Tensions Persist.

30 Aug 2026, 23:51 UTC

Cryptocurrency Markets Decline Amid Geopolitical Tensions and Commodity Shock Warnings, with Key Economic Data Releases Ahead.

30 Aug 2026, 23:51 UTC

Cryptocurrency markets decline as hedge funds sell tech stocks, while looming commodity shocks and geopolitical tensions raise inflation concerns ahead of key U.S. and Canadian labor data releases.

30 Aug 2026, 23:51 UTC

Cryptocurrency markets decline as hedge funds sell tech stocks; Japan's economic indicators reveal consumer spending trends amid global uncertainties, while Barclays warns of a commodity shock from El Niño.

30 Aug 2026, 23:51 UTC

Brazil's S&P Global Services PMI set for release on September 3, with analysts wary of further contraction following August's drop to 49.7 amid rising costs and political uncertainties.

30 Aug 2026, 23:51 UTC

Australia's Building Permits Expected to Decline by 4.8% in July Amidst Economic Pressures and Market Volatility

30 Aug 2026, 23:51 UTC

EUR/DKK remains effectively unchanged in after-market trading, showing unusual stability within a narrow band around its one-month trading range midpoint.

30 Aug 2026, 23:51 UTC

Correlated Moves

Gold Ounce vs Euro is trading lower, continuing a five-session decline, influenced by falling Silver and cautious sentiment amid forecasts of a commodity shock.

30 Aug 2026, 23:51 UTC

News

Bitcoin is trading lower today, despite earlier gains and social media discussions about Steak 'n Shake's Bitcoin initiative and potential AI investor interest.

30 Aug 2026, 23:51 UTC

Bitcoin is trading lower during Sunday’s session amid heightened volatility. The price remains above its 20-day moving average and near its one-month range.

30 Aug 2026, 23:42 UTC

Correlated Moves

The Nasdaq 100 Index is lower during Sunday’s session, reflecting broader market caution amid concerns over potential commodity shocks and adverse weather patterns.

30 Aug 2026, 23:41 UTC

Japan's Industrial Production Expected to Decline in July Amid Global Economic Concerns and Commodity Supply Chain Disruptions.

30 Aug 2026, 23:41 UTC

U.S. Unemployment Rate Release on September 4, 2026 Expected at 4.2%, Amid Cautious Optimism and Potential Fed Policy Implications

30 Aug 2026, 23:41 UTC

US Average Hourly Earnings Expected to Rise 0.2% Amid Cautious Market Sentiment on Wage Growth and Inflation Concerns

30 Aug 2026, 23:41 UTC

Labor Force Participation Rate in the U.S. Declines to 61.4%, Raising Concerns Ahead of September 2026 Data Release

30 Aug 2026, 23:41 UTC

Investors Anticipate Key U.S. Average Hourly Earnings Data Amid Rising Inflation Concerns Ahead of September 4 Release

30 Aug 2026, 23:41 UTC

US Non-Farm Payrolls Expected to Rise by Only 45K Jobs in August Amid Growing Employment Concerns

30 Aug 2026, 23:41 UTC

Canada's Unemployment Rate Expected to Decrease Slightly to 6.4% Amidst Economic Challenges and Improved Employment Figures

30 Aug 2026, 23:41 UTC

Canada's Labor Force Participation Rate Release on September 4, 2026, May Reflect Employment Dynamics Amid Housing Initiatives.

30 Aug 2026, 23:41 UTC

Canada's Employment Change Forecast for August 2026 Predicts +15.8K Jobs Amid Positive Labor Market Sentiment Following July's Surprising Gain of +75.1K Positions

30 Aug 2026, 23:41 UTC

Canada's Full-Time Employment Change Report Set for Release on September 4, Amid Economic Concerns and Political Developments.

30 Aug 2026, 23:41 UTC

Canada's Part-Time Employment Change Report Set for September 4, 2026, Amid Cautious Optimism in Labor Market Dynamics.

30 Aug 2026, 23:31 UTC

Correlated Moves

Avalanche is trading lower amid broader market sentiment, reflecting volatility. The asset remains above its 20-day moving average despite today's decline.

30 Aug 2026, 23:31 UTC

Terra is trading lower today amid ongoing volatility and remains below its 20-day moving average, reflecting a decline since Saturday's session.

30 Aug 2026, 23:31 UTC

Japan's Retail Sales Expected to Rise 0.03% YoY in July Amid Cautious Economic Sentiment and Weak Bond Market Performance

30 Aug 2026, 23:31 UTC

Correlated Moves

XRP is declining during Sunday’s session amid notable volatility, aligning with a drop in Bitcoin. The asset remains above its 20-day moving average.

Peer Comparison

Price change

Actinium Pharmaceuticals Inc Forecast

Price Target

By TipRanks

246.53% upside

12 Months Forecast

Average 3.5 USD 246.53%

High 4 USD

Low 3 USD

Based on 2 Wall Street analysts offering 12 month price targets forActinium Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Based on 2 analysts giving stock ratings to Actinium Pharmaceuticals Inc - Dist in the past 3 months.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.